Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biweekly Carboplatin, Gemcitabine, and Bevacizumab in Advanced NSCLC
NCT00400803Phase 2Completed
- Sponsor
- Masonic Cancer Center
- Start
- Mar 2007
- Primary completion
- May 2010
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of bevacizumab in non-small cell lung cancer (NSCLC), sponsored by Masonic Cancer Center. Primary endpoint: Time to Progression at 2 years. Started Mar 2007; status: completed.
02
Drugs
bevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00400803.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00400803.